Analysts Set Expectations for GLUE Q4 Earnings

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Free Report) - Stock analysts at Wedbush issued their Q4 2026 earnings estimates for Monte Rosa Therapeutics in a research report issued on Thursday, May 8th. Wedbush analyst R. Driscoll forecasts that the company will post earnings of ($0.57) per share for the quarter. Wedbush has a "Outperform" rating and a $17.00 price objective on the stock. The consensus estimate for Monte Rosa Therapeutics' current full-year earnings is ($1.49) per share.

Monte Rosa Therapeutics (NASDAQ:GLUE - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported $0.57 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.81.

GLUE has been the topic of several other research reports. Lifesci Capital initiated coverage on Monte Rosa Therapeutics in a report on Wednesday, March 12th. They issued an "outperform" rating and a $19.00 price target on the stock. Wells Fargo & Company cut their price target on Monte Rosa Therapeutics from $11.00 to $10.00 and set an "equal weight" rating on the stock in a report on Friday, March 21st.

Monte Rosa Therapeutics Trading Down 2.6%

Shares of NASDAQ GLUE opened at $4.11 on Monday. The company has a market cap of $252.81 million, a price-to-earnings ratio of -2.25 and a beta of 1.52. Monte Rosa Therapeutics has a 12-month low of $3.21 and a 12-month high of $12.40. The stock's 50 day simple moving average is $5.05 and its 200 day simple moving average is $6.54.

Institutional Trading of Monte Rosa Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD raised its stake in Monte Rosa Therapeutics by 7.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,116,637 shares of the company's stock valued at $49,391,000 after acquiring an additional 515,496 shares in the last quarter. Versant Venture Management LLC bought a new stake in shares of Monte Rosa Therapeutics in the 4th quarter worth $39,231,000. Vanguard Group Inc. raised its stake in shares of Monte Rosa Therapeutics by 24.5% in the 4th quarter. Vanguard Group Inc. now owns 3,156,354 shares of the company's stock worth $21,905,000 after buying an additional 622,134 shares in the last quarter. BVF Inc. IL bought a new stake in shares of Monte Rosa Therapeutics in the 4th quarter worth $19,185,000. Finally, Marshall Wace LLP raised its stake in shares of Monte Rosa Therapeutics by 187.3% in the 4th quarter. Marshall Wace LLP now owns 499,492 shares of the company's stock worth $3,466,000 after buying an additional 325,643 shares in the last quarter. Institutional investors own 79.96% of the company's stock.

Insider Buying and Selling at Monte Rosa Therapeutics

In other Monte Rosa Therapeutics news, Director Chandra P. Leo bought 10,000 shares of the business's stock in a transaction on Monday, March 24th. The shares were purchased at an average price of $5.84 per share, with a total value of $58,400.00. Following the purchase, the director now directly owns 10,000 shares of the company's stock, valued at approximately $58,400. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. 6.90% of the stock is owned by company insiders.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.